跳至主要内容
临床试验/NCT02797548
NCT02797548已完成4 期

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

Jung-min Ahn35 个研究点 分布在 3 个国家目标入组 1,010 人开始时间: 2017年3月16日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,010
试验地点
35
主要终点
The event rate of composite event of all-cause death, stent thrombosis, myocardial infarction, and stroke

研究概览

简要总结

The purpose of this study is to evaluate the safety and effectiveness of perioperative antiplatelet therapy in patients with drug-eluting stent undergoing non-cardiac surgery.

详细描述

Subjects who can not be randomized due to any reason will be enrolled at observational group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Planned non-cardiac surgery at least after 12 months of implantation of drug eluting stent
  • Low or intermediate risk level surgery
  • Written informed consent

排除标准

  • Acute coronary syndrome within 1 month
  • Heart failure NYHA III to IV
  • Contraindication to Aspirin
  • On anticoagulant therapy
  • Emergent surgery
  • Cardiac surgery
  • High bleeding risk surgeries, e.g., Intra-cranial surgery, Intra-spinal surgery, Retinal surgery
  • Pregnancy or breast-feeding
  • Life expectancy less than 1year

研究组 & 干预措施

Aspirin only

Experimental

干预措施: Aspirin only (Drug)

No antiplatelet therapy

Active Comparator

干预措施: No antiplatelet therapy (Drug)

结局指标

主要结局

The event rate of composite event of all-cause death, stent thrombosis, myocardial infarction, and stroke

时间窗: 30 days

A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.

次要结局

  • The event rate of all cause death(30 days)
  • The event rate of stroke(30 days)
  • The event rate of stent thrombosis(30 days)
  • The event rate of cardiac death(30 days)
  • The event rate of myocardial infarction(30 days)
  • The event rate of repeat revascularization(30 days)
  • The event rate of life threatening bleeding(30 days)
  • The event rate of major bleeding(30 days)
  • Quality of life score assessed by the EQ-5D-5L(30 days)
  • Quality of life score assessed by Health-related Quality of Life Instrument with 8 Items (HINT-8)(30 days)
  • Cost-effective analysis(30 days)

研究者

发起方
Jung-min Ahn
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jung-min Ahn

Assistant Professor

Asan Medical Center

研究点 (35)

Loading locations...

相似试验